FY2026 EPS Estimates for Ekso Bionics Decreased by Analyst

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) – Analysts at HC Wainwright reduced their FY2026 EPS estimates for Ekso Bionics in a research note issued to investors on Tuesday, October 29th. HC Wainwright analyst S. Ramakanth now anticipates that the company will post earnings of $0.02 per share for the year, down from their prior forecast of $0.03. HC Wainwright currently has a “Buy” rating and a $9.00 target price on the stock. The consensus estimate for Ekso Bionics’ current full-year earnings is ($0.42) per share. HC Wainwright also issued estimates for Ekso Bionics’ FY2027 earnings at $0.20 EPS and FY2028 earnings at $0.43 EPS.

Ekso Bionics (NASDAQ:EKSO) last posted its quarterly earnings data on Monday, October 28th. The company reported ($0.10) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.02). The firm had revenue of $4.13 million for the quarter, compared to analysts’ expectations of $6.00 million. Ekso Bionics had a negative return on equity of 92.08% and a negative net margin of 68.41%. During the same quarter last year, the firm posted ($0.24) earnings per share.

Other equities research analysts have also issued research reports about the stock. Lake Street Capital dropped their target price on shares of Ekso Bionics from $2.50 to $2.00 and set a “buy” rating for the company in a report on Tuesday. StockNews.com initiated coverage on shares of Ekso Bionics in a research note on Saturday, October 26th. They set a “hold” rating for the company.

Ekso Bionics Stock Down 2.9 %

Shares of EKSO opened at $0.93 on Wednesday. The stock has a 50 day moving average price of $1.11 and a 200 day moving average price of $1.15. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.77 and a current ratio of 2.42. The stock has a market capitalization of $16.94 million, a price-to-earnings ratio of -0.96 and a beta of 1.45. Ekso Bionics has a one year low of $0.83 and a one year high of $3.13.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Ekso Bionics stock. Kent Lake Capital LLC boosted its position in shares of Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) by 322.3% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 596,050 shares of the company’s stock after purchasing an additional 454,892 shares during the period. Kent Lake Capital LLC owned approximately 3.28% of Ekso Bionics worth $811,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 6.42% of the company’s stock.

Ekso Bionics Company Profile

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.